(ceftazidime for injection)
For Intravenous or Intramuscular Use
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration.
FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:
- Lower Respiratory Tract Infections, including pneumonia, caused by
spp.; Haemophilus influenzae,
including ampicillin-resistant strains; Klebsiella
spp.; Proteus mirabilis; Escherichia coli; Serratia
spp.; Streptococcus pneumoniae;
- Skin and Skin Structure Infections caused by
Pseudomonas aeruginosa; Klebsiella
spp.; Escherichia coli; Proteus
spp.; Staphylococcus aureus
(methicillin-susceptible strains); and
(group A beta-hemolytic streptococci).
- Urinary Tract Infections, both complicated and uncomplicated, caused by
Pseudomonas aeruginosa; Enterobacter
- Bacterial Septicemia caused by
Pseudomonas aeruginosa, Klebsiella
spp., Haemophilus influenzae, Escherichia coli, Serratia
spp., Streptococcus pneumoniae,
- Bone and Joint Infections caused by
Pseudomonas aeruginosa, Klebsiella
- Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by
- Intra-abdominal Infections, including peritonitis caused by
Escherichia coli, Klebsiella
(methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and
spp. (many strains of
- Central Nervous System Infections, including meningitis, caused by
Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to
FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used.
FORTAZ may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Media Articles Related to Fortaz (Ceftazidime)
Positive Phase III results demonstrate efficacy of AVYCAZ in complicated urinary tract infections
Source: Urology / Nephrology News From Medical News Today [2015.09.03]
Allergan plc. has announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ™ (ceftazidime-avibactam) as a treatment for adult...
Published Studies Related to Fortaz (Ceftazidime)
Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [2011.07.01]
RATIONALE: In experimental pneumonia, nebulization of antibiotics provides high lung tissue concentrations and rapid bacterial killing. OBJECTIVES: To assess the efficacy and safety of nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa... CONCLUSIONS: Nebulization and intravenous infusion of ceftazidime and amikacin provide similar efficiency for treating ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Nebulization is efficient against intermediate strains and may prevent per-treatment acquisition of antibiotic resistance.
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. [2009.10]
BACKGROUND/AIM: We hypothesized that a continuous 24-h infusion of 100 mg/kg per day ceftazidime (treatment C) would result in equivalent or even superior anti-infectious efficacy in chronic Pseudomonus aeruginosa (PA) infection in patients with cystic fibrosis (CF) in comparison to the usual application of 200 mg/kg per day ceftazidime in three doses (treatment T)... CONCLUSION: We conclude that continuous or thrice-daily dosing of intravenous ceftazidime, both combined with once-daily tobramycin, are equally effective application regimens for elective antipseudomonal therapy in clinically stable patients with CF.
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. [2009.04]
CONCLUSIONS: PIPC/TAZ+CAZ and SBT/ABPC+AZT are effective and safe for initial empirical treatment of febrile episodes in neutropenic pediatric patients. The clinical efficacy of SBT/ABPC+AZT is equivalent or superior to that of PIPC/TAZ+CAZ, the effect of which is already proven against febrile neutropenia. Therefore, SBT/ABPC+AZT may be a treatment of choice for febrile neutropenia in pediatric cancer patients.
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. [2008.03.01]
BACKGROUND: A randomized, double-blind, multicenter trial involving patients with a broad range of complicated skin and skin-structure infections due to either gram-positive or gram-negative bacteria was conducted to compare ceftobiprole monotherapy with treatment with vancomycin plus ceftazidime... CONCLUSIONS: Ceftobiprole monotherapy is as effective as vancomycin plus ceftazidime for treating patients with a broad range of complicated skin and skin-structure infections and infections due to gram-positive and gram-negative bacteria.
Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. [2006.02]
Piperacillin/tazobactam was compared with ceftazidime for the empirical treatment of febrile neutropenia in patients with acute leukemia or following autologous peripheral blood stem cell transplantation. Owing to inclusion criteria, it was possible for the same patient to be randomized several times.
Clinical Trials Related to Fortaz (Ceftazidime)
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia [Completed]
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers [Completed]
Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma [Completed]
Post ERCP Pancreatitis Prevention in Average Risk Patients [Completed]
Diclophenac potassium and ceftazidime are commercially available drugs that are used in
various clinical situations. They are safe and known for years. Diclophenac potassium and
Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis
and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is
currently standard treatment for prevention of (PEP) while ceftazidime is possible
alternative treatment for patients with contraindications for nonsteroidal medicines. The
aim of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.
Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections [Completed]
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus
Metronidazole compared to Meropenem for treating hospitalized patients with complicated
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Fortaz has an overall score of 8. The effectiveness score is 10 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Fortaz review by 50 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || UTI|
|Dosage & duration:|| || 250 mg bid taken as directed for the period of 7days|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || got rid of the uti, however, it took longer than d-mannose a non-prescription otc natural sugar which also had no side-effects|
|Side effects:|| || vaginal yeast infection which required treatment|
|Comments:|| || This drug got rid of the infection, however, since that time I have discovered d-mannose from the health food store it works faster and does not have any side effects, is cheaper, no doctor visit required|
Page last updated: 2015-09-03